Johnson & Johnson's 3 Most Promising Drugs
There's no bigger or broader a health care firm on the markets than Johnson & Johnson . This medical giant sells everything from orthopedic devices to bandages, but it's J&J's top-of-the-line pharmaceuticals that get Wall Street really excited. No other industry has the power to delight -- or disappoint -- like the pharmaceutical industry, and for Johnson & Johnson's drug business, it's done more of the former over the past.
With the patent cliff hitting sales across the industry, however, let's take a look ahead. Which of J&J's drugs have the most promise for the future, and which will investors across health care be talking about for years to come? In the video below, Motley Fool contributor Dan Carroll takes you through three of J&J's most exciting young and developing pharmaceuticals -- and what you can expect from these blossoming stars.
Blockbuster drugs play in a high-risk, high-reward game, but the best health care stocks can provide your portfolio rewards for years-or in Johnson & Johnson's case, decades. For a long-term investor, there's nothing better than such a stable, reliable stock at the foundation of your financial freedom. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.
The article Johnson & Johnson's 3 Most Promising Drugs originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
